| Bioactivity | Goserelin-d7 (TFA) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer[1][2]. |
| Formula | C65H80D7F9N18O20 |
| Molar Mass | 1618.52 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Ning Zhang, et al. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway. Oncol Rep. 2018 Mar; 39(3): 1034–1042. [3]. Halle C F Moore, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015 Mar 5;372(10):923-32. |
Goserelin-d7 TFA
CAS: F: C65H80D7F9N18O20 W: 1618.52
Goserelin-d7 (TFA) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releas
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.